Our why: patient access to life-saving & life-changing therapies where existing options are severely limited or opportunity exists to disrupt existing pathways to better patient care.
Our how: integrating market access/commercial strategies at all stages to transform great science from bench to clinic that regulators will approve, payers will pay, physicians will adopt, and from which patients will benefit.
Efficiency in development
Our portfolio-based model enables us to advance programs efficiently and de-risk investment. A centralized team works alongside asset-level “General Managers” & subject matter experts, enabling an acute focus on developing each therapy, while prioritizing experiments and iteratively & rigorously evaluating each program to de-risk early. This efficiency further leverages our clinical, market access and commercialization expertise across the portfolio, allowing us to scale a robust and potentially transformative pipeline. By ensuring each asset has a dedicated team, we are able to focus on driving rapid program advancement while ensuring there are clear paths through to approval, reimbursement, adoption and patient access.